• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硼替佐米通过抑制前列腺癌细胞中的 Wnt/β-连环蛋白信号通路增强米托蒽醌的抗肿瘤活性。

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.

机构信息

Institute of Precision Medicine, Jining Medical University, Jining, 272067, China.

Center for Experimental Medicine, School of Public Health, Jining Medical University, Jining, 272067, China.

出版信息

BMC Cancer. 2021 Oct 13;21(1):1101. doi: 10.1186/s12885-021-08841-1.

DOI:10.1186/s12885-021-08841-1
PMID:34645397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8515742/
Abstract

BACKGROUND

Bortezomib (BZM), alone or in combination with other chemotherapies, has displayed strong anticancer effects in several cancers. The efficacy of the combination of BZM and mitoxantrone (MTX) in treating prostate cancer remains unknown.

METHODS

Anticancer effects of combination of BZM and MTX were determined by apoptosis and proliferation assay in vivo and in vitro. Expression of β-Catenin and its target genes were characterized by western blot and Real-time PCR.

RESULTS

BZM significantly enhanced MTX-induced antiproliferation in vivo and in vitro. Mice administered a combination of BZM and MTX displayed attenuated tumor growth and prolonged survival. BZM significantly attenuated MTX-induced apoptosis. Moreover, the combination of BZM and MTX contributed to inhibition of the Wnt/β-Catenin signaling pathway compared to monotherapy.

CONCLUSIONS

This study demonstrates that BZM enhances MTX-induced anti-tumor effects by inhibiting the Wnt/β-Catenin signaling pathway in prostate cancer cells.

摘要

背景

硼替佐米（BZM）单独或与其他化疗药物联合使用在多种癌症中显示出强大的抗癌作用。BZM 与米托蒽醌（MTX）联合治疗前列腺癌的疗效尚不清楚。

方法

通过体内和体外的细胞凋亡和增殖实验来确定 BZM 和 MTX 联合的抗癌效果。通过 Western blot 和实时 PCR 来研究 β-连环蛋白及其靶基因的表达。

结果

BZM 显著增强了 MTX 在体内和体外诱导的增殖抑制作用。给予 BZM 和 MTX 联合治疗的小鼠显示出肿瘤生长减弱和存活时间延长。BZM 显著减弱了 MTX 诱导的细胞凋亡。此外，与单药治疗相比，BZM 和 MTX 的联合使用有助于抑制 Wnt/β-连环蛋白信号通路。

结论

本研究表明，BZM 通过抑制 Wnt/β-连环蛋白信号通路增强了 MTX 诱导的前列腺癌细胞的抗肿瘤作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/69b37cab05f4/12885_2021_8841_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/fd1a4092f54d/12885_2021_8841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/fed834d078e2/12885_2021_8841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/805a87400371/12885_2021_8841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/a2a645f48cc1/12885_2021_8841_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/ddc77d4bc49e/12885_2021_8841_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/69b37cab05f4/12885_2021_8841_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/fd1a4092f54d/12885_2021_8841_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/fed834d078e2/12885_2021_8841_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/805a87400371/12885_2021_8841_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/a2a645f48cc1/12885_2021_8841_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/ddc77d4bc49e/12885_2021_8841_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e653/8515742/69b37cab05f4/12885_2021_8841_Fig6_HTML.jpg

相似文献

1
Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.硼替佐米通过抑制前列腺癌细胞中的 Wnt/β-连环蛋白信号通路增强米托蒽醌的抗肿瘤活性。
BMC Cancer. 2021 Oct 13;21(1):1101. doi: 10.1186/s12885-021-08841-1.
2
Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.地西他滨联合蛋白酶体抑制剂硼替佐米通过 Wnt/β-连环蛋白通路治疗多发性骨髓瘤的协同疗效。
Oncol Res. 2019 Jun 21;27(6):729-737. doi: 10.3727/096504018X15443011011637. Epub 2019 Mar 5.
3
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.蛋白酶体抑制剂可减弱米托蒽醌诱导的前列腺癌细胞免疫原性细胞死亡。
Med Oncol. 2020 Nov 19;37(12):116. doi: 10.1007/s12032-020-01445-y.
4
Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway.青蒿素和奥沙利铂联合治疗通过 Wnt/β-连环蛋白信号通路抑制食管癌 EC109 细胞的肿瘤发生。
Thorac Cancer. 2020 Aug;11(8):2316-2324. doi: 10.1111/1759-7714.13570. Epub 2020 Jul 12.
5
Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway.竹节香附素 A 通过下调 Wnt/β-连环蛋白和 NF-κB 信号通路抑制人结直肠癌细胞的生长并诱导其凋亡。
Life Sci. 2018 Aug 15;207:532-549. doi: 10.1016/j.lfs.2018.06.035. Epub 2018 Jul 1.
6
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling.抗生素药物替加环素通过抑制Wnt/β-连环蛋白信号通路对宫颈鳞状细胞癌的治疗作用
Biochem Biophys Res Commun. 2015 Nov 6;467(1):14-20. doi: 10.1016/j.bbrc.2015.09.140. Epub 2015 Sep 30.
7
Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.促肾上腺皮质激素原（SKF-525A）下调 BCRP 和抗凋亡蛋白导致米托蒽醌耐药的人早幼粒细胞白血病细胞中米托蒽醌蓄积增加和毒性增强。
Int J Oncol. 2015 Oct;47(4):1572-84. doi: 10.3892/ijo.2015.3116. Epub 2015 Aug 6.
8
Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.驱虫药吡维铵靶向Wnt/β-连环蛋白可增强卵巢癌细胞对化疗的敏感性。
Med Sci Monit. 2017 Jan 16;23:266-275. doi: 10.12659/msm.901667.
9
β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.β-连环蛋白抑制剂 BC2059 作为单药治疗或与蛋白酶体抑制剂硼替佐米联合治疗多发性骨髓瘤有效。
Mol Cancer Ther. 2017 Sep;16(9):1765-1778. doi: 10.1158/1535-7163.MCT-16-0624. Epub 2017 May 12.
10
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.抑制 Wnt/β-catenin 信号通路可增强索拉非尼对肝癌的抗肿瘤作用。
Cancer Lett. 2016 Oct 10;381(1):58-66. doi: 10.1016/j.canlet.2016.07.013. Epub 2016 Jul 16.

引用本文的文献

1
The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells.转录轴ERK-Elk1、JNK-cJun和JAK-STAT促进前列腺癌细胞中的自噬激活和蛋白酶体抑制剂抗性。
Curr Issues Mol Biol. 2025 May 12;47(5):352. doi: 10.3390/cimb47050352.
2
A subcomponent-guided deep learning method for interpretable cancer drug response prediction.基于子组件指导的深度学习方法用于可解释的癌症药物反应预测。
PLoS Comput Biol. 2023 Aug 21;19(8):e1011382. doi: 10.1371/journal.pcbi.1011382. eCollection 2023 Aug.
3
Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development.

本文引用的文献

1
Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation.自噬介导的纤溶酶原激活物抑制剂-1分泌通过调节肿瘤微环境促进黑色素瘤对化疗的抵抗。
Cancers (Basel). 2021 Mar 12;13(6):1253. doi: 10.3390/cancers13061253.
2
Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.米托蒽醌通过依赖 p53 的 PERK 表达触发免疫原性前列腺癌细胞死亡。
Cell Oncol (Dordr). 2020 Dec;43(6):1099-1116. doi: 10.1007/s13402-020-00544-2. Epub 2020 Jul 24.
3
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.
硼替佐米诱导的神经细胞表观遗传学改变：关注导致周围神经病发展的机制。
Int J Mol Sci. 2022 Feb 23;23(5):2431. doi: 10.3390/ijms23052431.
硼替佐米治疗可调节多发性骨髓瘤中的自噬。
J Clin Med. 2020 Feb 18;9(2):552. doi: 10.3390/jcm9020552.
4
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.Wnt/β-连环蛋白信号通路与前列腺癌治疗抵抗
Adv Exp Med Biol. 2019;1210:351-378. doi: 10.1007/978-3-030-32656-2_16.
5
Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature.含硼替佐米方案成功治疗非IgM淋巴浆细胞淋巴瘤：病例报告及文献综述
Blood Res. 2019 Sep;54(3):236-240. doi: 10.5045/br.2019.54.3.236. Epub 2019 Sep 25.
6
Systemic treatment for metastatic prostate cancer.转移性前列腺癌的全身治疗。
Asian J Urol. 2019 Apr;6(2):162-168. doi: 10.1016/j.ajur.2019.02.002. Epub 2019 Feb 11.
7
Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.SOX9、Wnt/β-连环蛋白和雄激素受体信号在去势抵抗性前列腺癌中的相互作用。
Int J Mol Sci. 2019 Apr 26;20(9):2066. doi: 10.3390/ijms20092066.
8
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.硼替佐米治疗血液系统恶性肿瘤：15 年后。
Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9.
9
The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.蛋白酶体抑制剂硼替佐米通过抑制前列腺特异性膜抗原和雄激素受体的表达诱导前列腺癌细胞死亡。
Int J Oncol. 2019 Apr;54(4):1357-1366. doi: 10.3892/ijo.2019.4706. Epub 2019 Feb 1.
10
Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.阿特诺尔通过扰乱前列腺癌细胞的克雷布斯循环来消除过多的 ATP 生成。
Prostate. 2019 May;79(6):628-639. doi: 10.1002/pros.23767. Epub 2019 Jan 20.